Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Research & Development (2022 - 2025)

Summit Therapeutics' Research & Development history spans 4 years, with the latest figure at $147.3 million for Q4 2025.

  • For Q4 2025, Research & Development rose 186.66% year-over-year to $147.3 million; the TTM value through Dec 2025 reached $537.7 million, up 256.6%, while the annual FY2025 figure was $537.7 million, 256.6% up from the prior year.
  • Research & Development reached $147.3 million in Q4 2025 per SMMT's latest filing, up from $131.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $208.0 million in Q2 2025 to a low of $5.4 million in Q4 2022.
  • Average Research & Development over 4 years is $55.0 million, with a median of $30.8 million recorded in 2024.
  • Peak YoY movement for Research & Development: decreased 10.12% in 2023, then skyrocketed 575.44% in 2025.
  • A 4-year view of Research & Development shows it stood at $5.4 million in 2022, then surged by 360.71% to $24.8 million in 2023, then skyrocketed by 107.07% to $51.4 million in 2024, then skyrocketed by 186.66% to $147.3 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Research & Development are $147.3 million (Q4 2025), $131.1 million (Q3 2025), and $208.0 million (Q2 2025).